cefpodoxime proxetil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, cefalosporanic acid derivatives 555 87239-81-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cefpodoxime proxetil
  • cefpodoxime acid
  • cefodox
  • cefoprox
  • cephpodoxime proxetil
  • cepodem
Prodrug for cefpodoxime
  • Molecular weight: 557.59
  • Formula: C21H27N5O9S2
  • CLOGP: 0.90
  • LIPINSKI: 2
  • HAC: 14
  • HDO: 2
  • TPSA: 180.97
  • ALOGS: -4.04
  • ROTB: 13
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.40 g O
0.40 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.30 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 17.93 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 52 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 2.286 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 6.295 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 51.642 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 22.751 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 9.110 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 11.090 % High 1
herg hERG pIC50 4.546 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 50.466 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 246.037 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 6.080 % High 1
kinase-safety-class ACVR2A,ACVR2B,AKT2,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,ITK,JAK2,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MARK4,MET,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKDC,STK33,SYK,TEK,TTK 43
kinase-selectivity-class AXL,BRAF,CDK9,DDR1,EPHB4,GRK2,MAP2K6,MAPK7,STK33,SYK,TEK,TTK 12
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 19.679 Moderate 0.75
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 9.954 High 1
mh-clint Mouse hepatocyte intrinsic clearance 162.181 High 1
mppb Mouse plasma protein binding (% unbound) 10.750 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 57.412 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 10.580 % High 1
rat-kpuu-brain Rat brain Kpuu 0.065 % Moderate 0.75
rh-clint Rat hepatocyte intrinsic clearance 167.109 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 64.850 % High 1
rppb Rat plasma protein binding (% unbound) 10.190 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 408.319 uM High 1

Approvals:

DateAgencyCompanyOrphan
Aug. 7, 1992 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cystitis bacterial 28.20 25.74 5 1686 346 90626410
Arthritis reactive 25.80 25.74 5 1686 563 90626193

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pyrexia 31.00 23.98 63 2326 898202 109688708
Clostridium difficile colitis 27.45 23.98 15 2374 43763 110543147
Pneumonia 25.05 23.98 57 2332 876657 109710253

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01DD13 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
Third-generation cephalosporins
ATC J01DD64 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
Third-generation cephalosporins
FDA CS M0003827 Cephalosporins
FDA EPC N0000175488 Cephalosporin Antibacterial
CHEBI has role CHEBI:33282 antibacterial agent
CHEBI has role CHEBI:36047 antibacterial drug
CHEBI has role CHEBI:50266 prodrug
MeSH PA D000097902 beta Lactam Antibiotics
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000900 Anti-Bacterial Agents

Related Drugs by ATC class:

J01DD Third-generation cephalosporins 17 drugs
cefcapenecefdinircefditoren pivoxilcefetametcefiximecefmenoximecefodizimecefoperazonecefotaximecefpiramidecefsulodinceftazidime show all 17 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Acute otitis media indication 3110003
Gonorrhea indication 15628003 DOID:7551
Haemophilus Influenzae Acute Otitis Media indication 19021002
Infection of skin AND/OR subcutaneous tissue indication 19824006
Acute gonococcal cervicitis indication 20943002 DOID:10615
Acute gonococcal urethritis indication 29864006
Pneumonia due to Streptococcus indication 34020007
Streptococcal tonsillitis indication 41582007
Gonorrhea of rectum indication 42746002
Bacterial pneumonia indication 53084003 DOID:874
Klebsiella cystitis indication 60867007
Acute maxillary sinusitis indication 68272006 DOID:2050
Haemophilus influenzae pneumonia indication 70036007
Acute bacterial sinusitis indication 75498004
Tonsillitis indication 90176007 DOID:10456
Acute Moraxella catarrhalis bronchitis indication 195722003
Acute bacterial bronchitis indication 233598009
Pneumococcal pneumonia indication 233607000
Escherichia coli urinary tract infection indication 301011002
Proteus urinary tract infection indication 301012009
Streptococcus pyogenes infection indication 302809008
Bacterial urinary infection indication 312124009
Infective otitis media indication 312218008
Pharyngitis indication 405737000 DOID:2275
Infection due to Staphylococcus aureus indication 406602003
Acute exacerbation of chronic bronchitis indication 425748003
Moraxella Catarrhalis Acute Otitis Media indication 703469002
Streptococcus Pneumoniae Bronchitis indication
Staphylococcus Saprophyticus Urinary Tract Infection indication
Pneumococcal Acute Otitis Media indication
Haemophilus Influenzae Chronic Bronchitis indication
Blood coagulation disorder contraindication 64779008 DOID:1247
Factor II deficiency contraindication 73975000
Disease of liver contraindication 235856003 DOID:409
Pseudomembranous enterocolitis contraindication 397683000




🐶 Veterinary Drug Use

SpeciesUseRelation
Dogs Skin infections caused by Staphylococcus intermedius Indication
Dogs Skin infections caused by Staphylococcus aureus Indication
Dogs Skin infections caused by Streptococcus canis Indication
Dogs Skin infections caused by Escherchia coli Indication
Dogs Skin infections caused by Pasteurella multocida Indication
Dogs Skin infections caused by Proteus mirabilis Indication

🐶 Veterinary products

ProductApplicantIngredients
Simplicef Zoetis Inc. 1
Cefpodoxime Proxetil Tablets Dechra Veterinary Products LLC 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.1 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4020567 VUID
N0000148269 NUI
D00920 KEGG_DRUG
20489 RXNORM
C0108938 UMLSCUI
CHEMBL1201016 ChEMBL_ID
D000097627 MESH_DESCRIPTOR_UI
2TB00A1Z7N UNII
6526396 PUBCHEM_CID
DB01416 DRUGBANK_ID
4381 MMSL
57686 MMSL
d00095 MMSL
387534007 SNOMEDCT_US
96049003 SNOMEDCT_US
96050003 SNOMEDCT_US
C0055011 UMLSCUI
CHEMBL1672 ChEMBL_ID
80210-62-4 SECONDARY_CAS_RN
6335986 PUBCHEM_CID
10780 IUPHAR_LIGAND_ID
6123 INN_ID
4020567 VANDF
D000097623 MESH_DESCRIPTOR_UI
7R4F94TVGY UNII
003727 NDDF
003728 NDDF
CHEBI:3504 CHEBI
2TB00A1Z7N INXIGHT DRUGS
7R4F94TVGY INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Cefpodoxime Proxetil HUMAN PRESCRIPTION DRUG LABEL 1 0781-5438 TABLET, FILM COATED 100 mg ORAL ANDA 26 sections
Cefpodoxime Proxetil HUMAN PRESCRIPTION DRUG LABEL 1 0781-5439 TABLET, FILM COATED 200 mg ORAL ANDA 26 sections
CEFPODOXIME PROXETIL Human Prescription Drug Label 1 16714-394 TABLET, FILM COATED 100 mg ORAL ANDA 24 sections
CEFPODOXIME PROXETIL Human Prescription Drug Label 1 16714-395 TABLET, FILM COATED 200 mg ORAL ANDA 24 sections
Cefpodoxime Proxetil Human Prescription Drug Label 1 16714-402 GRANULE, FOR SUSPENSION 50 mg ORAL ANDA 24 sections
Cefpodoxime Proxetil Human Prescription Drug Label 1 16714-403 GRANULE, FOR SUSPENSION 100 mg ORAL ANDA 24 sections
Cefpodoxime Proxetil HUMAN PRESCRIPTION DRUG LABEL 1 51407-083 TABLET, FILM COATED 100 mg ORAL ANDA 23 sections
Cefpodoxime Proxetil HUMAN PRESCRIPTION DRUG LABEL 1 51407-084 TABLET, FILM COATED 200 mg ORAL ANDA 23 sections
CEFPODOXIME PROXETIL HUMAN PRESCRIPTION DRUG LABEL 1 55289-393 TABLET, FILM COATED 200 mg ORAL ANDA 23 sections
Cefpodoxime Proxetil Human Prescription Drug Label 1 64980-402 GRANULE, FOR SUSPENSION 50 mg ORAL ANDA 23 sections
Cefpodoxime Proxetil Human Prescription Drug Label 1 64980-403 GRANULE, FOR SUSPENSION 100 mg ORAL ANDA 23 sections
CEFPODOXIME PROXETIL Human Prescription Drug Label 1 65862-095 TABLET, FILM COATED 100 mg ORAL ANDA 23 sections
CEFPODOXIME PROXETIL Human Prescription Drug Label 1 65862-096 TABLET, FILM COATED 200 mg ORAL ANDA 23 sections
Cefpodoxime Proxetil Human Prescription Drug Label 1 65862-140 GRANULE, FOR SUSPENSION 50 mg ORAL ANDA 24 sections
Cefpodoxime Proxetil Human Prescription Drug Label 1 65862-141 GRANULE, FOR SUSPENSION 100 mg ORAL ANDA 24 sections
Cefpodoxime Proxetil Human Prescription Drug Label 1 67877-559 TABLET, FILM COATED 100 mg ORAL ANDA 23 sections
Cefpodoxime Proxetil Human Prescription Drug Label 1 67877-560 TABLET, FILM COATED 200 mg ORAL ANDA 23 sections
Cefpodoxime Proxetil Human Prescription Drug Label 1 67877-878 TABLET, FILM COATED 100 mg ORAL ANDA 23 sections
Cefpodoxime Proxetil Human Prescription Drug Label 1 67877-879 TABLET, FILM COATED 200 mg ORAL ANDA 23 sections
CEFPODOXIME PROXETIL HUMAN PRESCRIPTION DRUG LABEL 1 68071-2742 TABLET, FILM COATED 100 mg ORAL ANDA 24 sections
Cefpodoxime Proxetil HUMAN PRESCRIPTION DRUG LABEL 1 68071-3441 TABLET, FILM COATED 200 mg ORAL ANDA 23 sections
Cefpodoxime Proxetil HUMAN PRESCRIPTION DRUG LABEL 1 68071-3616 TABLET, FILM COATED 100 mg ORAL ANDA 23 sections
CEFPODOXIME PROXETIL Human Prescription Drug Label 1 69043-006 TABLET, FILM COATED 100 mg ORAL ANDA 24 sections
CEFPODOXIME PROXETIL Human Prescription Drug Label 1 69043-007 TABLET, FILM COATED 200 mg ORAL ANDA 24 sections
Cefpodoxime Proxetil Human Prescription Drug Label 1 69292-514 TABLET, FILM COATED 100 mg ORAL ANDA 23 sections
Cefpodoxime Proxetil Human Prescription Drug Label 1 69292-516 TABLET, FILM COATED 200 mg ORAL ANDA 23 sections
Cefpodoxime Proxetil HUMAN PRESCRIPTION DRUG LABEL 1 70518-4676 TABLET, FILM COATED 200 mg ORAL ANDA 23 sections